Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes
Currently, the only practical way to treat type 1 and advanced insulin-dependent type 2 diabetes mellitus (T1/2DM) is the frequent subcutaneous injection of insulin, which is significantly different physiologically from endogenous insulin secretion from pancreatic islets and can lead to hyperinsulinemia, pain, and infection in patients with poor compliance.
Highlights
- Oral administration of insulin mimics the endogenous insulin secretion.
- Strategies for PLGA nanoparticles to overcome different barriers for oral insulin delivery are discussed.
- Challenges and future perspectives of PLGA nanoparticles for oral insulin delivery are also put forward.
Hence, oral insulin delivery has been actively pursued to revolutionize the treatment of insulin-dependent diabetes. In this review, we provide an overview of recent progress in developing poly(lactic co-glycolic acid) (PLGA) nanoparticles (NPs) for oral insulin delivery. Different strategies for insulin-loaded PLGA NPs to achieve normoglycemic effects are discussed. Finally, challenges and future perspectives of PLGA NPs for oral insulin delivery are put forward.
Huiwen Pang, Xiangquan Huang, Zhi Ping Xu, Chen Chen, Felicity Y Han, Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes, Drug Discovery Today, 2022, 103393, ISSN 1359-6446, https://doi.org/10.1016/j.drudis.2022.103393